Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Syndax Announces Participation in November Investor Conferences

· Issued by Syndax Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing cancer therapies, said CEO Michael A. Metzger and members of its management team will take part in four investor conferences in November 2026, each with a fireside chat (an informal on-stage question-and-answer session).

Key details

  • Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA: fireside chat on Tuesday, November 10, 2026, at 11:00 a.m. ET.
  • Stifel 2026 Healthcare Conference in New York, NY: fireside chat on Thursday, November 12, 2026, at 9:20 a.m. ET.
  • UBS Global Biopharma Conference 2026 in London, UK: fireside chat on Tuesday, November 17, 2026, at 12:00 p.m. GMT / 7:00 a.m. ET.
  • Jefferies London Healthcare Conference in London, UK: fireside chat on Thursday, November 19, 2026, at 12:30 p.m. GMT / 7:30 a.m. ET.
  • Live webcasts of the fireside chats will be available in the Investor section of Syndax's website, with replays available for a limited time.

6ix AI wrote this summary from the release below and checked it against the release.

NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA with a fireside chat on Tuesday, November 10, 2026, at 11:00 a.m. ET.
  • Stifel 2026 Healthcare Conference in New York, NY with a fireside chat on Thursday, November 12, 2026, at 9:20 a.m. ET.
  • UBS Global Biopharma Conference 2026 in London, UK with a fireside chat on Tuesday, November 17, 2026, at 12:00 p.m. GMT / 7:00 a.m. ET.
  • Jefferies London Healthcare Conference in London, UK with a fireside chat on Thursday, November 19, 2026, at 12:30 p.m. GMT / 7:30 a.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G

View original source (GlobeNewswire)Syndax Pharmaceuticals, Inc. on 6ix

In the deck

Story so far

Earlier from Syndax Pharmaceuticals

Later from Syndax Pharmaceuticals

All Syndax Pharmaceuticals news releases